Liquid biopsy represents a new and minimally invasive method of finding and tracking cancer through the blood or other body fluids. The session "Liquid Biopsy" highlights some of the most recent breakthroughs in this technology, enabling clinicians to receive vital tumor information without taking conventional tissue biopsies.
This strategy examines circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers in the blood to offer real-time information on tumor genetics, cancer progression, and response to treatment. Liquid biopsy offers early cancer detection, monitoring of minimal residual disease, and detection of rising mutations that can impact therapy decisions.
The session also looks into the real-world applications of liquid biopsy in personal medicine. With knowledge of tumor evolution along the course of time, physicians are able to tailor treatment more accurately, enhancing the results while avoiding unnecessary interventions. It also aids clinical trials by offering a pain-free way of monitoring patient response and assessing new treatments.
Participants will discover the present technologies, clinical usefulness, and potential of liquid biopsy in oncology. This session highlights how liquid biopsy is defining the future of cancer diagnostics, including more rapid, safer, and more efficient methods to direct patient care as well as improve treatment strategies."
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
